18,240 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by Cinctive Capital Management LP

Cinctive Capital Management LP bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 18,240 shares of the biopharmaceutical company's stock, valued at approximately $4,292,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Groupama Asset Managment boosted its position in shares of Alnylam Pharmaceuticals by 0.5% in the fourth quarter. Groupama Asset Managment now owns 1,528,450 shares of the biopharmaceutical company's stock valued at $359,660,000 after acquiring an additional 7,065 shares during the period. Geode Capital Management LLC lifted its stake in Alnylam Pharmaceuticals by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 2,206,800 shares of the biopharmaceutical company's stock worth $518,367,000 after purchasing an additional 59,597 shares in the last quarter. National Bank of Canada FI boosted its holdings in Alnylam Pharmaceuticals by 9.0% in the 4th quarter. National Bank of Canada FI now owns 668 shares of the biopharmaceutical company's stock valued at $157,000 after purchasing an additional 55 shares during the period. Edmond DE Rothschild Holding S.A. purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $63,000. Finally, Allstate Corp bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth $894,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Trading Down 0.7 %

Alnylam Pharmaceuticals stock traded down $1.58 during trading hours on Tuesday, reaching $231.37. The stock had a trading volume of 255,899 shares, compared to its average volume of 845,204. The company has a fifty day simple moving average of $258.16 and a 200-day simple moving average of $259.83. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The stock has a market cap of $30.10 billion, a PE ratio of -106.89 and a beta of 0.30. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Remove Ads

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on ALNY shares. Sanford C. Bernstein reduced their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. Canaccord Genuity Group boosted their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a report on Friday, March 21st. Needham & Company LLC restated a "buy" rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Wells Fargo & Company lifted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research report on Friday, March 21st. Finally, Stifel Nicolaus increased their price target on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a report on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $316.25.

Insider Activity

In other news, CFO Jeffrey V. Poulton sold 967 shares of the firm's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the sale, the chief financial officer now directly owns 32,786 shares of the company's stock, valued at approximately $8,366,003.62. This trade represents a 2.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of the business's stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. This represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,234 shares of company stock valued at $19,958,097. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.